This Biotech Stock Could Double Overnight

New Drug Candidate To Target Most Aggressive Type Of Brain Cancer Received Positive FDA Pre-IND Guidance Dear Reader, The NASDAQ stock exchange is abundant with emerging growth biotech stocks, but there is one company that is on our radar that is targeting the most aggressive type of brain cancer that was developed at the largest cancer treatment and research institute in the world. They recently IPO'd at $4 per share and they are preparing to begin their Phase II clinical trials. We've put together a detailed report on why we believe it offers investors a unique opportunity in the biotech space. Click here for more details. ©2019 Trade Stocks. All Rights Reserved. RISK DISCLAIMER: Before deciding to participate in any investment, you should carefully consider your investment objectives, level of experience and risk tolerance. Most importantly, do not invest money you cannot afford to lose. Trade Stocks is not a registered broker-dealer. Trade Stocks does not give investment advice, endorsement, analysis or recommendations with respect to any securities. Trade Stocks has not taken any steps to verify the adequacy, accuracy or completeness of any information. Neither Trade Stocks nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information on this site or the use of information on this site. By accessing this site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy. Trade Stocks does not make investment recommendations and no communication, through this website or in any other medium should be construed as an investment recommendation. Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. Additionally, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.

This is a paid communication provided to customers/subscribers to DailyMarketAlerts. Although we have sent you this email, DailyMarketAlerts does NOT specifically endorse this product nor is it responsible for the content of this communication. Furthermore, we make no guarantee or warranty about what is communicated above.


DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that DailyMarketAlerts is being paid on a cost-per-click basis which may exceed a fee of $1,000.00 in cash, from a third party as compensation for the distribution of this communication. DailyMarketAlerts has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this communication, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely upon. Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.